Summary The administration of nicotine during the perinatal stages of life resulted in a significant decrease in tumours occurring after transplacental induction by N-methylnitrosourea (MNU). The overall tumour incidence following p.o. application of MNU to dams was 85% in rats of the F,-generation, the main occurrence being related to the neurogenic system (62% of the animals). Regular injections of nicotine before or after birth resulted in a reduction of malignancies by 17% and 22% (P=0.08 and 0.0015), respectively. The difference in the incidence of neurogenic tumours proved to be highly significant (P<0.002) in rats of either sex, when nicotine was applied over 26 weeks following birth. There was a gender-specific imbalance in rats which received the carcinogen only, in favour of a lower tumour yield in females (P<0.04), which became less apparent when nicotine was given additionally. These findings suggest that nicotine is capable of modulating the expression of chemically induced tumours of the neurogenic system in a favourable way. Antonomov, 1976) . The importance of the respective single agents in tobacco smoke in the mechanisms of tumour development is the field of current research. To avoid a multitude of concurrent mechanisms that are active in tobacco smoke, it seems necessary to investigate at first the effects of purified compounds in order to identify their inherent risk precisely.
Numerous epidemiologic and clinical studies indicate a high correlation between smoking and various types of cancer. To date, the causative factors of neoplasms associated with smoking habits have not been identified with certainty. Tobacco smoke itself is a very complex mixture containing a variety of different classes of carcinogens such as nitrosamines (Druckrey & Preussmann, 1962) or polycyclic aromatic hydrocarbons (Yanysheva & Antonomov, 1976) . The importance of the respective single agents in tobacco smoke in the mechanisms of tumour development is the field of current research. To avoid a multitude of concurrent mechanisms that are active in tobacco smoke, it seems necessary to investigate at first the effects of purified compounds in order to identify their inherent risk precisely.
Since nicotine is the main attraction when consuming cigarettes, this constituent was primarily tested for a possible carcinogenic action. The majority of these studies revealed that neither nicotine nor its primary metabolites were carcinogenic (LaVoie et al., 1985; Martin et al., 1979; Schmahl & Osswald, 1968; Toth, 1982) , although two studies indicated a weak tumorigenic action (Boyland, 1968; Truhaut et al., 1984) . Furthermore, a limited number of studies were concerned with a possible modulation of carcinogenesis by nicotine (Bock, 1980; Gurkalo & Volfson, 1982;  Habs & Schmahl, 1976 & Schmahl, , 1984 Ito et al., 1984; LaVoie et al., 1985) . These authors used well-established chemicallyinduced models for the detection of nicotine-related changes in tumour expression. Since no uniform answer was obtained from these studies, the question remains whether certain types of cancer can be influenced specifically by nicotine (Bock, 1980; Gurkalo & Volfson, 1982; LaVoie et al., 1985) and whether especially sensitive periods of life exist such as the perinatal period, in which even a very low dose of this agent can lead to tumour development. The latter assumption could be relevant, since a remarkable number of women do not change their smoking habits during pregnancy and subsequent lactation period. This is the case, even though the influence of nicotine on the progeny has been established in terms of underweight births in animals as well as man (Becker et al., 1968; Becker & Martin, 1971; Martin et al., 1979 Peto et al. (1980) .
Results
No influence of the treatment on either duration of pregnancy (21 days + 2 days) or the average number of surviving descendants per litter (13 + 1) was seen. In comparison with the groups not receiving MNU (groups III, V? VI; Figure 1 ) transplacental administration of 30mgkg-1 MNU (group I, II, IV) significantly decreased the body wt gain in both males and females. Injections of nicotine did not affect this parameter and neither did they cause symptoms of acute or subacute toxicity. The long-term toxicologic effect of MNU administration resulted in an overall malignancy rate of 85% (Group I, Table II ). These tumours were mainly of neurogenic origin (62% incidence in the F,-generation), additionally 3% of the progeny showed tumours of the kidney and 30% of the females had tumours of the mammary gland. Histologically, 85% of the neurogenic tumours were found to be sarcomas, located in the peritoneal cavity or associated with the spinal cord. The remaining tumours of the nervous system proved to be gliomas (7%) and neurinomas (7%) in type. The genderspecific subdivision of MNU-treated animals presented a similar overall tumour incidence. Significant differences, however, were observed with regard to the occurrence of the two main tumour types: 30% less females presented with neurogenic tumours (P<0.04; compared to males) and the females experienced mammary lesions (P<0.01) in contrast to the males.
At termination of the experiment, 97% of the males and 80% of the females had died of MNU-induced tumours.
Administration of nicotine before (Group II) or following Figure 1 Mean body weight gain in female (A) and male (B) SD-rats following transplacental induction with MNU (groups I , II* *, IV C] L) in relation to nicotine-treated (groups III A A, V 0 O) and -untreated controls (group VI *-----0).
(Group IV) birth resulted in a reduction of the overall load of malignant tumours to 68% and 63% (P=0.08 and 0.0015), respectively. This was due to a decrease in the number of malignancies of the nervous system and of the mammary gland. The occurrence of neurogenic tumours was reduced more when nicotine was administered over a period of 26 weeks following birth (Group IV vs. Group I; (48) 16 (55) 1 (3) 6 (20) 7 (24) 10 (34)bd P=0.0015) compared to the transplacental administration of nicotine (Group IV vs. Group II; P=0.08). Concomitant with the decreased occurrence of neurogenic tumours in rats treated with nicotine following birth, a shift in tumour type was observed from neurogenic sarcomas (70% instead of 85%) to gliomas (27% instead of 7%) compared with MNU-treated controls. Interestingly, the gender-specific imbalance in the occurrence of neurogenic tumours following MNU was diminished to an insignificant difference of 4% (P=0.4) in group II and of 14% (P=0.25) in group IV. The differences found in tumours of the mammary gland, however, were not significant according to an age-adjusted analysis of observed versus expected numbers of affected animals, although considerably less malignant mammary tumours appeared in both MNU and nicotine treated groups.
The regular injection of nicotine alone (groups III and V, respectively) had no overt influence on the survival or tumour yield in comparison to untreated controls.
Discussion
The directly acting carcinogen MNU is well known to induce a variety of tumours, depending on the time and route of administration (Berger & Schmahl, 1986; IARC Monographs, 1978) . In a first study on the modulation of MNU-induced tumorigenesis by nicotine in sexually premature rats, no apparent differences were obtained in the development of mammary tumours (Habs & Schmahl, 1984) . This study was designed to assess the influence of nicotine on the same carcinogen during the perinatal stages of life. No influence on tumour development was exerted by nicotine alone (groups III and V versus group IV); this finding is in accordance with previously published data (Martin et al., 1979) . In comparison to a study by Alexandrov (1976) (Habs & Schmahl, 1976; Ivankovic & Druckrey, 1968) . At the same dose (mg kg-1 bodywt) ENU caused an incidence of neurogenic tumours of 92% in males and 90% in females. A gender-specific imbalance of neurogenic tumours was observed only at a dose of 10mgkg-1 ENU (62% incidence in males and 50% incidence in females), which was comparable to the results obtained in the present experiment. In contrast to this study, however, lifelong administration of nicotine (i.p.) resulted in 12% less neurogenic tumours in males, but in 16% more neurogenic tumours in females. Thus, nicotine did not significantly modulate the carcinogenic potential of ENU following transplacental administration.
Similar to that study, no change in the yield of urinary bladder tumours was obtained when nicotine was administered to N-butyl-N-(4-hydroxybutyl) nitrosamine-induced male F344 rats (Ito et al., 1984) . Unlike this result a significant enhancement in the number of N-methyl-N-nitro-Nnitroso-guanidine-induced tumours of the glandular stomach was detected in male albino rats following coadministration of nicotine (Gurkalo & Volfson, 1982) . Another experiment which concentrated on the modification of N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide-induced tumours following administration of nicotine-derived metabolic products in male F344 rats, reported an increased total tumour load of rats, when these compounds were coadministered (LaVoie et al., 1985) . Interestingly, the incidence of urinary bladder tumours was significantly reduced. This is the only report which details an inhibitory effect of nicotine-related compounds on tumorigenesis, at least in one tissue. The results of the present study are even more surprising, since no complementary increase to the reduced occurrence of neurogenic tumours was detected in other tissues.
So far, no sufficient explanation is available for this inhibitory effect of nicotine on the development of neurogenic tumours. It might be speculated that the release of catecholamines caused by the administration of the neurotropic nicotine (Arqueros et al., 1978) resulted in specific mechanisms of action leading to growth inhibition of neoplasms of the ncurogenic tissue. In view of the reduced gender-specific differences in the observed tumour load following MNU and nicotine, the assumption of a hormonal influencc cannot be excluded. A direct influence of nicotine on the decomposition or pharmacokinetics of MNU can be excluded, however, at least in group IV, where the administration of the modulating agent started one day after injection of the carcinogen. It is furthermore interesting to note that the seemingly protective effect of nicotine was observed independently of the fact, whether nicotine was administered before or after birth of the animals. The results, of course, do not mean that nicotine should be regarded as a beneficial or even harmless agent, since all other studies (Gurkalo & Volfson, 1982; Habs & Schmahl, 1984; Ito et' al., 1984; LaVoie et al., 1985) , including one on the same type of tissue (Habs & Schmahl, 1976) , indicated an increased carcinogenic expression following this alkaloid or at least showed no apparent influence on experimental tumorigenesis. The observed unexpected modulation of carcinogenesis, however, warrants further investigations on compounds structurally related to MNU, such as alkylating cytotoxic agents.
